Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Report Second Quarter 2021 Financial Results
July 22, 2021 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021
June 04, 2021 08:00 ET | Travere Therapeutics, Inc.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
June 02, 2021 08:00 ET | Travere Therapeutics, Inc.
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Proposed Public Offering of Common Stock
February 10, 2021 16:01 ET | Travere Therapeutics, Inc.
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
January 12, 2021 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Provides Corporate Update and 2021 Outlook
January 11, 2021 07:00 ET | Travere Therapeutics, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
December 01, 2020 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to...